While drug maker Valeant Pharmaceuticals International Inc.'s dreams of buying Botox maker Allergan may be dead, the company's revenue growth seems alive and kicking. In October it reported same store organic sales growth of 19 per cent compared to the same period a year ago. A key question for investors is whether or not the growth can continue? Two directors appear to have put money on it. Over the past two weeks, Ron Framer bought 1,000 shares while Kate Stevenson bought 1,500. The two trades combined are worth about $412,274.
Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.
Infographic reflects public-market transactions of common shares or unit trusts by company officers and directors.
